Oncotarget

Research Papers:

SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-β1) signalling in renal cell carcinoma

Caiyun Grace Li _, Andrew Chantry, Cherie Stayner, Julia Horsfield and Michael R. Eccles

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:26852-26867. https://doi.org/10.18632/oncotarget.25516

Metrics: PDF 1461 views  |   HTML 2598 views  |   ?  


Abstract

Gagandeep Kaur1, Caiyun Grace Li1, Andrew Chantry2, Cherie Stayner1, Julia Horsfield1 and Michael R. Eccles1

1Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

2School of Biological Sciences, University of East Anglia, Norwich, United Kingdom

Correspondence to:

Michael R. Eccles, email: [email protected]

Keywords: TGF-β1 signalling; PAX2 expression; epithelial to mesenchymal transition; clear cell renal cell carcinoma; SMAD proteins

Received: January 10, 2018     Accepted: May 14, 2018     Published: June 01, 2018

ABSTRACT

Canonical TGF-β1 signalling promotes tumor progression by facilitating invasion and metastasis, whereby release of TGF-β1, by (for example) infiltrating immune cells, induces epithelial to mesenchymal transition (EMT). PAX2, a member of the Paired box family of transcriptional regulators, is normally expressed during embryonic development, including in the kidney, where it promotes mesenchymal to epithelial transition (MET). PAX2 expression is silenced in many normal adult tissues. However, in contrast, PAX2 is expressed in several cancer types, including kidney, prostate, breast, and ovarian cancer. While multiple studies have implicated TGF-β superfamily members in modulating expression of Pax genes during embryonic development, few have investigated direct regulation of Pax gene expression by TGF-β1. Here we have investigated direct regulation of PAX2 expression by TGF-β1 in clear cell renal cell carcinoma (CC-RCC) cell lines. Treatment of PAX2-expressing 786-O and A498 CC-RCC cell lines with TGF-β1 resulted in inhibition of endogenous PAX2 mRNA and protein expression, as well as expression from transiently transfected PAX2 promoter constructs; this inhibition was abolished in the presence of expression of the inhibitory SMAD, SMAD7. Using ChIP-PCR we showed TGF-β1 treatment induced SMAD3 protein phosphorylation in 786-O cells, and direct SMAD3 binding to the human PAX2 promoter, which was inhibited by SMAD7 over-expression. Overall, these data suggest that canonical TGF-β signalling suppresses PAX2 transcription in CC-RCC cells due to the direct binding of SMAD proteins to the PAX2 promoter. These studies improve our understanding of tumor progression and epithelial to mesenchyme transition (EMT) in CC-RCC and in other PAX2-expressing cancer types.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25516